Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 70

1.

Modeling of Effective Antimicrobials to Reduce Staphylococcus aureus Virulence Gene Expression Using a Two-Compartment Hollow Fiber Infection Model.

Shukla SK, Carter TC, Ye Z, Pantrangi M, Rose WE.

Toxins (Basel). 2020 Jan 22;12(2). pii: E69. doi: 10.3390/toxins12020069.

2.

Multicenter Cohort of Patients With Methicillin-Resistant Staphylococcus aureus Bacteremia Receiving Daptomycin Plus Ceftaroline Compared With Other MRSA Treatments.

McCreary EK, Kullar R, Geriak M, Zasowski EJ, Rizvi K, Schulz LT, Ouellette K, Vasina L, Haddad F, Rybak MJ, Zervos MJ, Sakoulas G, Rose WE.

Open Forum Infect Dis. 2019 Dec 31;7(1):ofz538. doi: 10.1093/ofid/ofz538. eCollection 2020 Jan.

3.

Ability of Bicarbonate Supplementation to Sensitize Selected Methicillin-Resistant Staphylococcus aureus (MRSA) Strains to β-Lactam Antibiotics in an Ex Vivo Simulated Endocardial Vegetation Model.

Rose WE, Bienvenida AM, Xiong YQ, Chambers HF, Bayer AS, Ersoy SC.

Antimicrob Agents Chemother. 2019 Dec 16. pii: AAC.02072-19. doi: 10.1128/AAC.02072-19. [Epub ahead of print]

PMID:
31844004
4.

Development of a vaccine against Staphylococcus aureus invasive infections: Evidence-based on human immunity, genetics, and bacterial evasion mechanisms.

Miller LS, Fowler VG, Shukla SK, Rose WE, Proctor RA.

FEMS Microbiol Rev. 2019 Dec 16. pii: fuz030. doi: 10.1093/femsre/fuz030. [Epub ahead of print]

PMID:
31841134
5.

IL-1β and IL-10 Host Responses in Patients with Staphylococcus aureus Bacteremia Determined by Antimicrobial Therapy.

Volk CF, Burgdorf S, Edwardson G, Nizet V, Sakoulas G, Rose WE.

Clin Infect Dis. 2019 Aug 1. pii: ciz686. doi: 10.1093/cid/ciz686. [Epub ahead of print]

PMID:
31365924
6.

Antimicrobial stewardship during a time of rapid antimicrobial development: Potential impact on industry for future investment.

Schulz LT, Kim SY, Hartsell A, Rose WE.

Diagn Microbiol Infect Dis. 2019 Nov;95(3):114857. doi: 10.1016/j.diagmicrobio.2019.06.009. Epub 2019 Jun 22.

PMID:
31327622
7.

Geographic Mapping of Escherichia coli Susceptibility To Develop a Novel Clinical Decision Support Tool.

Legenza L, Barnett S, Lacy JP, See C, Desotell N, Eibergen A, Piccirillo JF, Rose WE.

Antimicrob Agents Chemother. 2019 May 24;63(6). pii: e00048-19. doi: 10.1128/AAC.00048-19. Print 2019 Jun.

8.

Comparison of risk factors and outcomes of daptomycin-susceptible and -nonsusceptible vancomycin-resistant enterococcus faecium infections in liver transplant recipients; A reply to Lewis et al.

Jorgenson MR, Descourouez JL, Leverson GE, Rose WE, Smith JA, Fernandez LA.

Transpl Infect Dis. 2018 Dec;20(6):e13004. doi: 10.1111/tid.13004. Epub 2018 Oct 19. No abstract available.

PMID:
30256505
9.

Data for vancomycin elution, activity and impact on mechanical properties when incorporated into orthopedic bone cement.

Bishop AR, Kim S, Squire M, Rose WE, Ploeg HL.

Data Brief. 2018 Jul 17;20:14-19. doi: 10.1016/j.dib.2018.07.028. eCollection 2018 Oct.

10.

GW779439X and Its Pyrazolopyridazine Derivatives Inhibit the Serine/Threonine Kinase Stk1 and Act As Antibiotic Adjuvants against β-Lactam-Resistant Staphylococcus aureus.

Schaenzer AJ, Wlodarchak N, Drewry DH, Zuercher WJ, Rose WE, Ferrer CA, Sauer JD, Striker R.

ACS Infect Dis. 2018 Oct 12;4(10):1508-1518. doi: 10.1021/acsinfecdis.8b00136. Epub 2018 Aug 15.

11.

Vancomycin elution, activity and impact on mechanical properties when added to orthopedic bone cement.

Bishop AR, Kim S, Squire MW, Rose WE, Ploeg HL.

J Mech Behav Biomed Mater. 2018 Nov;87:80-86. doi: 10.1016/j.jmbbm.2018.06.033. Epub 2018 Jun 28.

PMID:
30048880
12.

Activity of Telavancin against Staphylococcus aureus Isolates, Including Those with Decreased Susceptibility to Ceftaroline, from Cystic Fibrosis Patients.

Roch M, Varela MC, Taglialegna A, Rose WE, Rosato AE.

Antimicrob Agents Chemother. 2018 Aug 27;62(9). pii: e00956-18. doi: 10.1128/AAC.00956-18. Print 2018 Sep.

13.

Characterization of genetic changes associated with daptomycin nonsusceptibility in Staphylococcus aureus.

Ma Z, Lasek-Nesselquist E, Lu J, Schneider R, Shah R, Oliva G, Pata J, McDonough K, Pai MP, Rose WE, Sakoulas G, Malik M.

PLoS One. 2018 Jun 7;13(6):e0198366. doi: 10.1371/journal.pone.0198366. eCollection 2018.

14.

Evaluation of Telavancin Alone and Combined with Ceftaroline or Rifampin against Methicillin-Resistant Staphylococcus aureus in an In Vitro Biofilm Model.

Jahanbakhsh S, Singh NB, Yim J, Rose WE, Rybak MJ.

Antimicrob Agents Chemother. 2018 Jul 27;62(8). pii: e00567-18. doi: 10.1128/AAC.00567-18. Print 2018 Aug.

15.

Daptomycin selects for genetic and phenotypic adaptations leading to antibiotic tolerance in MRSA.

Berti AD, Shukla N, Rottier AD, McCrone JS, Turner HM, Monk IR, Baines SL, Howden BP, Proctor RA, Rose WE.

J Antimicrob Chemother. 2018 Aug 1;73(8):2030-2033. doi: 10.1093/jac/dky148.

16.

Combination Antibiotic Exposure Selectively Alters the Development of Vancomycin Intermediate Resistance in Staphylococcus aureus.

Zheng X, Berti AD, McCrone S, Roch M, Rosato AE, Rose WE, Chen B.

Antimicrob Agents Chemother. 2018 Jan 25;62(2). pii: e02100-17. doi: 10.1128/AAC.02100-17. Print 2018 Feb.

17.

Multiple-Dose Oritavancin Evaluation in a Retrospective Cohort of Patients with Complicated Infections.

Schulz LT, Dworkin E, Dela-Pena J, Rose WE.

Pharmacotherapy. 2018 Jan;38(1):152-159. doi: 10.1002/phar.2057. Epub 2017 Dec 11.

PMID:
29121395
18.

Dissecting Out the Direct Impacts of Large-Scale Antimicrobial Stewardship Interventions on Clinical Outcomes: Can Confounding Be Overcome?

Dilworth TJ, Rose WE, Sakoulas G, Bayer AS.

Clin Infect Dis. 2017 Nov 13;65(11):1956-1957. doi: 10.1093/cid/cix676. No abstract available.

PMID:
29020207
19.

A screen for kinase inhibitors identifies antimicrobial imidazopyridine aminofurazans as specific inhibitors of the Listeria monocytogenes PASTA kinase PrkA.

Schaenzer AJ, Wlodarchak N, Drewry DH, Zuercher WJ, Rose WE, Striker R, Sauer JD.

J Biol Chem. 2017 Oct 13;292(41):17037-17045. doi: 10.1074/jbc.M117.808600. Epub 2017 Aug 16.

20.

Minocycline modulates NFκB phosphorylation and enhances antimicrobial activity against Staphylococcus aureus in mesenchymal stromal/stem cells.

Guerra AD, Rose WE, Hematti P, Kao WJ.

Stem Cell Res Ther. 2017 Jul 21;8(1):171. doi: 10.1186/s13287-017-0623-1.

21.

Vaccines in development for the primary prevention of Clostridium difficile infection.

Legenza LM, Barnett SG, Rose WE.

J Am Pharm Assoc (2003). 2017 Jul - Aug;57(4):547-549. doi: 10.1016/j.japh.2017.06.007. No abstract available.

PMID:
28712463
22.

Fosfomycin tromethamine for the Treatment of Cystitis in Abdominal Solid Organ Transplant Recipients With Renal Dysfunction.

Kerstenetzky L, Jorgenson MR, Descourouez JL, Leverson G, Rose WE, Redfield RR, Smith JA.

Ann Pharmacother. 2017 Sep;51(9):751-756. doi: 10.1177/1060028017710252. Epub 2017 May 16.

PMID:
28511545
23.

Increased Endovascular Staphylococcus aureus Inoculum Is the Link Between Elevated Serum Interleukin 10 Concentrations and Mortality in Patients With Bacteremia.

Rose WE, Shukla SK, Berti AD, Hayney MS, Henriquez KM, Ranzoni A, Cooper MA, Proctor RA, Nizet V, Sakoulas G.

Clin Infect Dis. 2017 May 15;64(10):1406-1412. doi: 10.1093/cid/cix157. Erratum in: Clin Infect Dis. 2017 Oct 15;65(8):1431-1433.

24.

Minocycline enhances the mesenchymal stromal/stem cell pro-healing phenotype in triple antimicrobial-loaded hydrogels.

Guerra AD, Rose WE, Hematti P, Kao WJ.

Acta Biomater. 2017 Mar 15;51:184-196. doi: 10.1016/j.actbio.2017.01.021. Epub 2017 Jan 7.

25.

Effectiveness and Safety of Tigecycline Compared with Other Broad-Spectrum Antimicrobials in Abdominal Solid Organ Transplant Recipients with Polymicrobial Intraabdominal Infections.

Liebenstein T, Schulz LT, Viesselmann C, Bingen E, Musuuza J, Safdar N, Rose WE.

Pharmacotherapy. 2017 Feb;37(2):151-158. doi: 10.1002/phar.1883. Epub 2017 Jan 26.

PMID:
27983753
26.

Modeling Meropenem Treatment, Alone and in Combination with Daptomycin, for KPC-Producing Klebsiella pneumoniae Strains with Unusually Low Carbapenem MICs.

Gagetti P, Pasteran F, Martinez MP, Fatouraei M, Gu J, Fernandez R, Paz L, Rose WE, Corso A, Rosato AE.

Antimicrob Agents Chemother. 2016 Jul 22;60(8):5047-50. doi: 10.1128/AAC.00168-16. Print 2016 Aug.

27.

Penicillin Binding Protein 1 Is Important in the Compensatory Response of Staphylococcus aureus to Daptomycin-Induced Membrane Damage and Is a Potential Target for β-Lactam-Daptomycin Synergy.

Berti AD, Theisen E, Sauer JD, Nonejuie P, Olson J, Pogliano J, Sakoulas G, Nizet V, Proctor RA, Rose WE.

Antimicrob Agents Chemother. 2015 Nov 2;60(1):451-8. doi: 10.1128/AAC.02071-15. Print 2016 Jan.

28.
29.

Heterogeneity of genetic pathways toward daptomycin nonsusceptibility in Staphylococcus aureus determined by adjunctive antibiotics.

Berti AD, Baines SL, Howden BP, Sakoulas G, Nizet V, Proctor RA, Rose WE.

Antimicrob Agents Chemother. 2015 May;59(5):2799-806. doi: 10.1128/AAC.04990-14. Epub 2015 Mar 2.

30.

Mesenchymal Stromal/Stem Cell and Minocycline-Loaded Hydrogels Inhibit the Growth of Staphylococcus aureus that Evades Immunomodulation of Blood-Derived Leukocytes.

Guerra AD, Cantu DA, Vecchi JT, Rose WE, Hematti P, Kao WJ.

AAPS J. 2015 May;17(3):620-30. doi: 10.1208/s12248-015-9728-6. Epub 2015 Feb 26.

31.

Compatibility of cefepime and vancomycin during simulated Y-site administration of prolonged infusion.

Berti AD, Hutson PR, Schulz LT, Webb AP, Rose WE.

Am J Health Syst Pharm. 2015 Mar 1;72(5):390-5. doi: 10.2146/ajhp140369.

PMID:
25694414
32.

The influence of low concentrations of a water soluble poragen on the material properties, antibiotic release, and biofilm inhibition of an acrylic bone cement.

Slane JA, Vivanco JF, Rose WE, Squire MW, Ploeg HL.

Mater Sci Eng C Mater Biol Appl. 2014 Sep;42:168-76. doi: 10.1016/j.msec.2014.05.026. Epub 2014 May 22.

PMID:
25063107
33.

Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline.

Sakoulas G, Moise PA, Casapao AM, Nonejuie P, Olson J, Okumura CY, Rybak MJ, Kullar R, Dhand A, Rose WE, Goff DA, Bressler AM, Lee Y, Pogliano J, Johns S, Kaatz GW, Ebright JR, Nizet V.

Clin Ther. 2014 Oct 1;36(10):1317-33. doi: 10.1016/j.clinthera.2014.05.061. Epub 2014 Jul 10.

PMID:
25017183
34.

Defining daptomycin resistance prevention exposures in vancomycin-resistant Enterococcus faecium and E. faecalis.

Werth BJ, Steed ME, Ireland CE, Tran TT, Nonejuie P, Murray BE, Rose WE, Sakoulas G, Pogliano J, Arias CA, Rybak MJ.

Antimicrob Agents Chemother. 2014 Sep;58(9):5253-61. doi: 10.1128/AAC.00098-14. Epub 2014 Jun 23.

35.

Prevention of biofilm formation by methacrylate-based copolymer films loaded with rifampin, clarithromycin, doxycycline alone or in combination.

Rose WE, Otto DP, Aucamp ME, Miller Z, de Villiers MM.

Pharm Res. 2015 Jan;32(1):61-73. doi: 10.1007/s11095-014-1444-x. Epub 2014 Jun 17.

PMID:
24934663
36.

Meningococcal serogroup B outbreaks and use of 4CMenB vaccine.

Rose WE.

J Am Pharm Assoc (2003). 2014 Mar-Apr;54(2):198-201. doi: 10.1331/JAPhA.2014.14512. No abstract available.

PMID:
24632933
37.

New pharmacological treatments for methicillin-resistant Staphylococcus aureus infections.

Burke SL, Rose WE.

Expert Opin Pharmacother. 2014 Mar;15(4):483-91. doi: 10.1517/14656566.2014.876991. Epub 2014 Jan 17. Review.

PMID:
24437531
38.

Daptomycin dosing based on ideal body weight versus actual body weight: comparison of clinical outcomes.

Ng JK, Schulz LT, Rose WE, Fox BC, Andes DR, Buhr KA, Fish JT.

Antimicrob Agents Chemother. 2014;58(1):88-93. doi: 10.1128/AAC.01018-13. Epub 2013 Oct 21.

39.

β-Lactam antibiotics targeting PBP1 selectively enhance daptomycin activity against methicillin-resistant Staphylococcus aureus.

Berti AD, Sakoulas G, Nizet V, Tewhey R, Rose WE.

Antimicrob Agents Chemother. 2013 Oct;57(10):5005-12. doi: 10.1128/AAC.00594-13. Epub 2013 Jul 29.

40.

The "epic" challenge of optimizing antimicrobial stewardship: the role of electronic medical records and technology.

Kullar R, Goff DA, Schulz LT, Fox BC, Rose WE.

Clin Infect Dis. 2013 Oct;57(7):1005-13. doi: 10.1093/cid/cit318. Epub 2013 May 10.

PMID:
23667260
41.

Relationship of in vitro synergy and treatment outcome with daptomycin plus rifampin in patients with invasive methicillin-resistant Staphylococcus aureus infections.

Rose WE, Berti AD, Hatch JB, Maki DG.

Antimicrob Agents Chemother. 2013 Jul;57(7):3450-2. doi: 10.1128/AAC.00325-12. Epub 2013 May 6.

42.

Alternative mutational pathways to intermediate resistance to vancomycin in methicillin-resistant Staphylococcus aureus.

Vidaillac C, Gardete S, Tewhey R, Sakoulas G, Kaatz GW, Rose WE, Tomasz A, Rybak MJ.

J Infect Dis. 2013 Jul;208(1):67-74. doi: 10.1093/infdis/jit127. Epub 2013 Mar 28.

43.

Fosfomycin synergy in vitro with amoxicillin, daptomycin, and linezolid against vancomycin-resistant Enterococcus faecium from renal transplant patients with infected urinary stents.

Descourouez JL, Jorgenson MR, Wergin JE, Rose WE.

Antimicrob Agents Chemother. 2013 Mar;57(3):1518-20. doi: 10.1128/AAC.02099-12. Epub 2012 Dec 21.

44.

Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic/pharmacodynamic model.

Werth BJ, Sakoulas G, Rose WE, Pogliano J, Tewhey R, Rybak MJ.

Antimicrob Agents Chemother. 2013 Jan;57(1):66-73. doi: 10.1128/AAC.01586-12. Epub 2012 Oct 15. Erratum in: Antimicrob Agents Chemother. 2013 Mar;57(3):1565.

45.

Structure and biosynthesis of the antibiotic bottromycin D.

Hou Y, Tianero MD, Kwan JC, Wyche TP, Michel CR, Ellis GA, Vazquez-Rivera E, Braun DR, Rose WE, Schmidt EW, Bugni TS.

Org Lett. 2012 Oct 5;14(19):5050-3. doi: 10.1021/ol3022758. Epub 2012 Sep 17.

46.

Elevated serum interleukin-10 at time of hospital admission is predictive of mortality in patients with Staphylococcus aureus bacteremia.

Rose WE, Eickhoff JC, Shukla SK, Pantrangi M, Rooijakkers S, Cosgrove SE, Nizet V, Sakoulas G.

J Infect Dis. 2012 Nov 15;206(10):1604-11. doi: 10.1093/infdis/jis552. Epub 2012 Sep 10.

47.

Genotypic and phenotypic evaluation of the evolution of high-level daptomycin nonsusceptibility in vancomycin-resistant Enterococcus faecium.

Humphries RM, Kelesidis T, Tewhey R, Rose WE, Schork N, Nizet V, Sakoulas G.

Antimicrob Agents Chemother. 2012 Nov;56(11):6051-3. doi: 10.1128/AAC.01318-12. Epub 2012 Sep 4.

48.

Addition of ceftaroline to daptomycin after emergence of daptomycin-nonsusceptible Staphylococcus aureus during therapy improves antibacterial activity.

Rose WE, Schulz LT, Andes D, Striker R, Berti AD, Hutson PR, Shukla SK.

Antimicrob Agents Chemother. 2012 Oct;56(10):5296-302. doi: 10.1128/AAC.00797-12. Epub 2012 Aug 6.

49.

Altering the proclivity towards daptomycin resistance in methicillin-resistant Staphylococcus aureus using combinations with other antibiotics.

Berti AD, Wergin JE, Girdaukas GG, Hetzel SJ, Sakoulas G, Rose WE.

Antimicrob Agents Chemother. 2012 Oct;56(10):5046-53. doi: 10.1128/AAC.00502-12. Epub 2012 Jul 16.

50.

Vancomycin tolerance in methicillin-resistant Staphylococcus aureus: influence of vancomycin, daptomycin, and telavancin on differential resistance gene expression.

Rose WE, Fallon M, Moran JJ, Vanderloo JP.

Antimicrob Agents Chemother. 2012 Aug;56(8):4422-7. doi: 10.1128/AAC.00676-12. Epub 2012 Jun 11.

Supplemental Content

Support Center